Vicarious Surgical, Inc. · OTC:RBOT
Vicarious Surgical — Q1 2025 Earnings Presentation
18 slides from Vicarious Surgical's earnings presentation, May 12, 2025
Slide 1: To Improve Lives by Transforming Robotic Surgery
To Improve Lives by Transforming Robotic Surgery
Slide 2: Disclaimer
V I C A R I O U S S U R G I C A L I N V E S TO R P R E S E N TAT I O N A P R I L 2 0 2 5 Disclaimer This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provi- sions of the United States Private Securities Litigation Reform Act of 1995. The company ’s actua
Slide 3: The Worlds Most Advanced Surgical Robot
V I C A R I O U S S U R G I C A L I N V E S TO R P R E S E N TAT I O N A P R I L 2 0 2 5 The Worlds Most Advanced Surgical Robot First Surgical Robot Designed for A Decade of R&D - Ready for First Human We Are Backed By Top-Tier Partners General Surgery Use in Late 2025 Attracted world’s largest sur
Slide 4: Our Journey
V I C A R I O U S S U R G I C A L I N V E S TO R P R E S E N TAT I O N A P R I L 2 0 2 5 Our Journey Leveraging over a decade of R&D and $300 million of investment. First Human Founding Core Beta 1 Regulatory Beta 2 V1.0 Ready Use De Novo Adam Sachs, Technology System Change System for Testing Submi
Slide 5: Extensive Market Opportunity
V I C A R I O U S S U R G I C A L I N V E S TO R P R E S E N TAT I O N A P R I L 2 0 2 5 $150 Billion • Hernia • Gallbladder • Gastrointestinal Extensive I N I T I A L M A R K E T O P P O R T U N I T Y: • Gynecology Market 45 Million Opportunity PROCEDURES ABDOMINAL ROBOTIC- ADDRESSABLE WORLDWIDE PE
Slide 6: Existing Robots Are Designed for Prostate Surgery
V I C A R I O U S S U R G I C A L I N V E S TO R P R E S E N TAT I O N A P R I L 2 0 2 5 Existing Robots Are Designed for Prostate Surgery 10 One of the lowest volume (yet highest margin) standard abdominal procedures. ROBOTIC OPEN & L APAROSCOPIC C H O L E C Y ST E C TO M Y 5% VENTR AL HERNIA 17% H
Slide 7: A History of Surgery
V I C A R I O U S S U R G I C A L I N V E S TO R P R E S E N TAT I O N A P R I L 2 0 2 5 A History of Surgery Vicarious 1846 1987 1999 2014 Surgical Open Surgery Laparoscopic Surgery Robotic/Laparoscopic First Gen Single Port Next Gen Single Port HIGH ACUITY & Intuitive HIGH COST SUPPORTS S TA P L E
Slide 8: The Vicarious Surgical Benefit
V I C A R I O U S S U R G I C A L I N V E S TO R P R E S E N TAT I O N A P R I L 2 0 2 5 The Vicarious Surgical Benefit Patient Outcomes Simplicity & Maneuverability Inside the Abdomen One Small Incision - Just 1.8cm3,4 Yesterday’s Multi-Port Today’s Single-Port OPEN TECHNIQUE- MIS TECHNIQUE- SCALPE
Slide 9: The Vicarious Surgical Benefit
V I C A R I O U S S U R G I C A L I N V E S TO R P R E S E N TAT I O N A P R I L 2 0 2 5 The Vicarious Surgical Benefit Hospital Economics Advanced Sensing & Visualization 12 Hour Shift Hospital Contribution5 Instrumented to Support a Future of AI Automation13 Multi-Port Vicarious Surgical Revenue $
Slide 10: Positioned for AI Automated Surgery
V I C A R I O U S S U R G I C A L I N V E S TO R P R E S E N TAT I O N M A R C H 2 0 2 5 Positioned for AI Automated Surgery Foundational technology enables future for advanced surgery. Highest Quality Data Capture 28 force and position sensors and 3 axis accelerometer per arm, two 9mm 12MP image se
Slide 11: Da Vinci by Intuitive vs Vera by Vicarious
V I C A R I O U S S U R G I C A L I N V E S TO R P R E S E N TAT I O N M A R C H 2 0 2 5 First Generation Architecture Next Generation Architecture Da Vinci by Intuitive Vera by Vicarious 58 -$10K 4% 19 +$6K 2025 MINUTES H O S P I TA L P R O F I T MARKET MINUTES H O S P I TA L P R O F I T ENTERING D
Slide 12: Prepared for Successful Commercial Launch
V I C A R I O U S S U R G I C A L I N V E S TO R P R E S E N TAT I O N A P R I L 2 0 2 5 Prepared for Successful Commercial Launch Laying the foundation with top hospital system partnerships. >1,000 SURGEONS >250 6 H O S P I TA L S S U B S TA N T I A L POTENTIAL USER BASE ACROSS OUR PARTNERS H O S P
Slide 13: Quick Cadence of Significant Development
V I C A R I O U S S U R G I C A L I N V E S TO R P R E S E N TAT I O N A P R I L 2 0 2 5 Quick Cadence of Significant Development After 4,000 days of development, we will be filing for human use in just 150 days. MID L AT E L AT E 2025 2025 2026 Regulatory submission for First Human Use Cases Start
Slide 14: Addressable Procedures
V I C A R I O U S S U R G I C A L I N V E S TO R P R E S E N TAT I O N A P R I L 2 0 2 5 Indication Stomach & intestinal: (5.4m) Colorectal: (4.2m) ~15.0M Appendectomies: (3.8m) GI PROCEDURES Pathway 1,2 Bariatric: (0.9M) ~3.1M US Pancreatic: (0.4m) Esophageal: (0.3m) ADDRESSABLE PROCEDURES ~5.6M Hy
Slide 15: Process in a Complex Program
V I C A R I O U S S U R G I C A L I N V E S TO R P R E S E N TAT I O N A P R I L 2 0 2 5 Process in a Complex Program New Leadership Has Brought a Foundation of Process to Vicarious Surgical People Process Execution The Right Team for Execution Industry Leading Processes and Standards Continue to Dr
Slide 16: Board and Executive Leadership
V I C A R I O U S S U R G I C A L I N V E S TO R P R E S E N TAT I O N A P R I L 2 0 2 5 Board and Executive Leadership Seasoned Investors21 Bill Gates BOARD DIRECTOR BOARD DIRECTOR BOARD DIRECTOR CO-FOUNDER, CHIEF MEDICAL OFFICER BOARD DIRECTOR VICTORIA RANDY CLARK RIC FULOP BARRY GREENE DAVID HO C
Slide 17: Thank You
V I C A R I O U S S U R G I C A L I N V E S TO R P R E S E N TAT I O N M A R C H 2 0 2 5 Thank You 78 Fourth Avenue vicarioussurgical.com Waltham, MA, 02451 +1.617.868.1700 17
Slide 18: Sources
V I C A R I O U S S U R G I C A L I N V E S TO R P R E S E N TAT I O N A P R I L 2 0 2 5 Sources 1. VS ESTIMATES FROM DATA SOURCED FROM LSI MARKET SIZE ANALYSIS 2022 DATA AND PUBLIC FILINGS. ASSUMES $3,319 REVENUE PER PROCEDURE CURRENTLY REALIZED BY LEGACY ROBOTIC COMPANY. 2. VS ESTIMATES FROM 2022